logo

IMRX

Immuneering·NASDAQ
--
--(--)
--
--(--)
2.80 / 10
Underperform

Fundamental assessment is underperform with a score of 2.8/10. Key weaknesses include low Net profit / Total profit at 100% (group 1, score 0) and a negative Asset-MV value of -0.5007 (group 2). Bullish factors such as Profit-MV (0.4634, group 1, score 2) and Cash-MV (-0.0673, group 1, score 2) provide some balance, but overall quality remains inadequate, warranting selective investment only.

Fundamental(2.8)SentimentTechnical

Analysis Checks(6/10)

Revenue-MV
Value-0.26
Score1/3
Weight10.15%
1M Return5.20%
Inventory turnover ratio
Value47.85
Score3/3
Weight8.92%
1M Return5.26%
Gross profit margin (%)
Value36.70
Score1/3
Weight-0.78%
1M Return-0.54%
Profit-MV
Value0.46
Score2/3
Weight15.19%
1M Return7.79%
PB-ROE
Value-0.01
Score1/3
Weight14.03%
1M Return7.02%
Current assets turnover ratio
Value1.78
Score2/3
Weight1.78%
1M Return1.15%
Fixed assets turnover ratio
Value7979.42
Score3/3
Weight1.30%
1M Return0.86%
Asset-MV
Value-0.50
Score2/3
Weight34.66%
1M Return15.13%
Cash-MV
Value-0.07
Score2/3
Weight15.21%
1M Return7.73%
Net profit / Total profit (%)
Value100.00
Score0/3
Weight-0.45%
1M Return-0.30%
Is IMRX fundamentally strong?
  • IMRX scores 2.80/10 on fundamentals and holds a Premium valuation at present. Backed by its -33.00% ROE, 0.00% net margin, -4.80 P/E ratio, 1.31 P/B ratio, and 9.14% earnings growth, these metrics solidify its Underperform investment rating.